Cardio-Kidney-Metabolic Complexity in Atrial Fibrillation
- Okay, here's a breakdown of the study methodology as described in the provided text, organized for clarity.
- * Patients are categorized based on the presence of components of the "CKM syndrome" (Cardiovascular, Kidney, Metabolic).
- * Treatments: * Antithrombotic Therapy: Use of Oral Anticoagulants (OACs) - specifically, whether they were Vitamin K Antagonists (VKAs) or Non-Vitamin K Antagonist Oral Anticoagulants (NOACs).
Okay, here’s a breakdown of the study methodology as described in the provided text, organized for clarity. it covers the study groups, data collected, follow-up, outcomes, and statistical analysis.
1. Study Population & Groups (CKM Syndrome Definition)
* The study uses data from the GLORIA-AF registry.
* Patients are categorized based on the presence of components of the “CKM syndrome” (Cardiovascular, Kidney, Metabolic).
* CKM Groups:
* 0 Domains: Patients with none of the CKM components.
* Single Domain: Patients with only Cardiovascular, Kidney, or Metabolic issues.
* Two Domains: Patients with Cardio-Kidney, Cardio-Metabolic, or Kidney-Metabolic combinations.
* All Domains: Patients with all three (Cardio-Kidney-Metabolic).
2. Data Collected at Baseline (Initial Assessment)
* Treatments:
* Antithrombotic Therapy: Use of Oral Anticoagulants (OACs) – specifically, whether they were Vitamin K Antagonists (VKAs) or Non-Vitamin K Antagonist Oral Anticoagulants (NOACs).
* Other Medications: ACE inhibitors, ARBs, diuretics, beta-blockers (selective & non-selective), digoxin, verapamil/diltiazem, propafenone, flecainide, amiodarone, dronedarone, other antiarrhythmics, statins, insulin, and oral hypoglycemic agents.
* interventional Procedures:
* AF ablation
* Cardioversion
3. Follow-up & Outcomes (Over 3 Years)
* All patients had a 3-year follow-up period.
* Outcomes Measured:
* Primary outcome: Composite of All-Cause Death and major Adverse Cardiovascular Events (MACE).
* Secondary (Exploratory) Outcomes:
* All-cause Mortality
* MACE (defined as cardiovascular death, stroke, and myocardial infarction)
* Thromboembolism (stroke, TIA, and other non-CNS thromboembolism)
* Major Bleeding (life-threatening/fatal, symptomatic in critical organ, Hb reduction ≥20g/L, or ≥2 units transfusion)
4. Statistical Analysis
* Continuous Variables: Reported as mean ± SD or median & IQR, compared using parametric or non-parametric tests.
* Categorical Variables: Reported as frequencies (percentages), compared using chi-square tests.
* Geographical Region Analysis: Multiple-adjusted logistic regression models were used to assess the association between geographical region (Europe, North America, Asia, Latin America) and the presence of each CKM domain.
* Covariate Adjustment: The logistic regression models included adjustments for:
* CHA2DS2-VASc score components (age, sex, hypertension, diabetes, CHF, CAD, PAD, stroke/TIA history)
* BMI
* Creatinine Clearance (CrCl)
* Type of AF (paroxysmal, persistent, permanent)
In essence, this study aims to determine how the presence and number of CKM syndrome components (cardiovascular, kidney, and metabolic issues) relate to treatment patterns and clinical outcomes in patients with atrial fibrillation.